Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?

Pfizer's oncology business is expanding, with Q1 2025 revenues up 7% operationally, driven by drugs like Xtandi and Padcev, and boosted by the 2023 acquisition of Seagen. The company is also advancing its clinical pipeline and exploring biosimilars, positioning it to compete with AstraZeneca, Merck, and Bristol-Myers Squibb in the oncology space; despite these positive developments, Pfizer's stock is down 6.8% YTD, but its valuation appears attractive relative to the industry, and 2025/2026 earnings estimates have been revised upwards.

Analysis

Pfizer's oncology division demonstrates robust growth and strategic expansion, underscored by a 7% operational revenue increase in Q1 2025, driven by key drugs such as Xtandi, Lorbrena, the Braftovi-Mektovi combination, and Padcev. The 2023 acquisition of Seagen has significantly bolstered Pfizer's capabilities, contributing meaningfully to revenues in 2024 and Q1 2025 through its four approved antibody-drug conjugates (ADCs) – Adcetris, Padcev, Tukysa, and Tivdak – and promising next-generation ADC candidates. Further strengthening its pipeline, Pfizer has advanced several candidates like sasanlimab, vepdegestrant, and sigvotatug vedotin into late-stage development and secured an exclusive licensing deal with China's 3SBio for a dual PD-1 and VEGF inhibitor. The company is also pursuing label expansions for established products and has a presence in oncology biosimilars with six marketed products. Despite these positive operational developments and a promising outlook in cancer treatment, Pfizer's stock (PFE) has underperformed, declining 6.8% year-to-date against a 0.2% increase for its industry. However, from a valuation perspective, PFE appears attractive, trading at a forward P/E ratio of 7.77, significantly below the industry average of 15.05 and its own 5-year mean of 10.90. This valuation is complemented by upward revisions in consensus earnings estimates for 2025 (from $2.98 to $3.06 per share) and 2026 (from $3.00 to $3.09 per share) over the past 60 days. The oncology market remains competitive, with major players like AstraZeneca (oncology sales comprising ~41% of total revenue, up 13% in Q1 2025), Merck (Keytruda accounting for ~50% of pharmaceutical sales), and Bristol-Myers (Opdivo representing ~20% of total revenues) also showing strong performance in this segment.

Key Decisions for Investors

• Given Pfizer's strong oncology pipeline development, successful Seagen integration, and recent 7% operational revenue growth in the segment, investors should assess the current stock underperformance as a potential valuation opportunity, especially considering its forward P/E of 7.77.
• Monitor the progress of late-stage oncology candidates such as sasanlimab and vepdegestrant, as well as the continued revenue contribution from acquired Seagen products, as these are key potential catalysts for future growth.
• Consider the upward revisions in 2025 and 2026 earnings estimates alongside the attractive valuation relative to peers and historical levels; this may warrant a re-evaluation of existing positions or new allocations for value-focused portfolios, while acknowledging the competitive landscape.